Neurodegenerative and cerebrovascular diseases are frequent in elderly populations and
comprise primarily of dementia (mainly Alzheimer's disease) Parkinson's disease and …

Neurodegenerative diseases affect over 30 million people worldwide with an ascending
trend. Most individuals suffering from these irreversible brain damages belong to the elderly …

In ischemic stroke, there is only one approved drug, tissue plasminogen activator, to be used
in clinical conditions for thrombolysis. New neuroprotective therapies for ischemic stroke are …

The manipulation of transmembrane signaling by G protein-coupled receptors (GPCRs)
constitutes perhaps the single most important therapeutic target in medicine. Therapeutics …

Highlights•GPCRs are implicated in the pathophysiology of various neurodegenerative
diseases.•Currently available therapies do not cure the discussed neurodegenerative …

Neurodegenerative diseases are a large group of neurological disorders with diverse
etiological and pathological phenomena. However, current therapeutics rely mostly on …

Neuropsychiatric disorders are multifactorial disorders with diverse aetiological factors.
Identifying treatment targets is challenging because the diseases are resulting from …

G protein‐coupled receptors (GPCRs) are intricately involved in the conversion of
extracellular feedback to intracellular responses. These specialized receptors possess a …

G protein coupled receptors (GPCRs) represent the most important targets in modern
pharmacology because of the different functions they mediate, especially within brain and …

G-protein coupled receptors (GPCRs) modulate diverse cellular responses to the majority of
neurotransmitters and hormones within the human body. They exhibit much structural and …